$194.71-2.8%Nov 13 close
Figures through September 30, 2026, from the 6-K filed October 27, 2026
ICON sells clinical-trial management, testing and patient-recruitment services to drug, biotechnology and medical-device companies and public-health organizations.
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $2B | $2.1B | -2.86% |
| Profit | $122.1M | -$284.2M | +142.98% |
| Profit per share | $1.58 | -$3.67 | +143.05% |
| Free Cash Flow | $307.1M | $333.9M | -8.01% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Icon plc has no earnings call transcript available.
ICON plc is a world-leading clinical research organization. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,250 employees in 98 locations in 55 countries as at September 30, 2026 .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Icon plc filed on October 27, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.